AAV Platform Advantage StrideBio’s structure-inspired AAV platform delivers evasion of pre-existing antibodies, tissue targeting, enhanced potency, and scalable manufacturability, creating opportunities for vector design collaborations, co-development, or licensing with partners seeking differentiated gene delivery solutions.

Manufacturing Footprint In-house manufacturing footprint enables rapid iteration and potential CDMO partnerships for others seeking scalable AAV production and fill-finish capabilities, presenting a clear sales angle for manufacturing services or joint process development.

Leadership and Funding Active leadership evolution and meaningful funding position StrideBio for strategic collaborations and co-development deals with larger pharma players seeking access to next-generation AAV vectors and pipeline acceleration.

Academic Partnerships Past collaboration with Duke and a track record of academic partnerships suggest a readiness to engage in research collaborations and patient-recruitment networks, offering opportunities to expand preclinical and translational programs with academia and biotech allies.

Patient Engagement Focus A demonstrated emphasis on patient engagement indicates potential to provide or co-create patient recruitment, engagement platforms, and outcomes research support to streamline clinical trial enrollment and improve trials for gene therapies.